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This manuscript is dedicated to several people who have 
been instrumental in influencing the person I have become. My 
father gave me my early exposure to clinical medicine and 
realization of the satisfactions it could provide. The inspira¬ 
tion to study medicine came from my mother, and she has been a 
constant source of encouragement. My mentor, Doctor Steven M. 
Horvath, taught me the intellectual satisfactions that could be 
derived from science, and provided me with.the essential direction 
and opportunities that has been the real impetus for me to pursue 
a career in medicine. Most of all, however, my wife have given 
me the contentment in life necessary to channel my energies. To 
all these people I want to say, "Thank you." 

ABSTRACT 
Cardiac prostaglandin (PG) release occurs after coronary 
occlusion. Indomethacin, which inhibits cardiac PG synthesis, 
has been shown to increase enicardial ST-segment elevation (STt ) 
over ischemic myocardium. In vitro data suggest that acetyl- 
salicylic acid (aspirin) may not affect myocardial PG synthetase, 
but inhibits PG in other tissues. This study examines the 
effects of aspirin on STt after left anterior descending (LAD) 
coronary occlusion in 15 open-chest dogs, compared to 5 con¬ 
trols. Aspirin (either 30 mg/kg, IV or 60 mg/kg, IV) or saline 
was infused at 63 min after occlusion. Sum of ST (S ST) and 
number of sites with 2 nm ST± (NST) were recorded at 60, 75, and 
90 min. 
2 ST (mean - SEM) was not significantly affected at 75 min 
by either 30 mg/kg or 60 mg/kg of aspirin (Control, 2.53 ± 0.28$ 
30 mg/kg, 3.24 ±0.17; 60 mg/kg, 4.81 ±0.51, p<0.01)* Nor was 
NST significantly affected (Control, 4.00 ±0.26; 30 mg/kg, 
6.00±0.14; 60 mg/kg, 5.00±0.35, p<0.01). Results at 90 min 
were similar for both lST and NST. 
Thus, unlike indomethacin, aspirin does not affect 1ST or 
NST. This may be due to membraneeffects or drug-specific dif¬ 
ferences in the inhibition of myocardial or vascular PG. 

PG History 
The history of prostaglandins began with the observations 
made by Kurzrok and Lieb (1930), both American gynecologists, 
that preparations of human uterus either relax or contract when 
exposed to human semen. A few years later in Sweden, Euler 
(1936) reported that seminal fluid and the accessory reproductive 
glands produced both smooth muscle contracting and vasodepressor 
activity. Similar work was done independently in England by 
Goldblatt (1935). Euler succeeded in identifying the active 
fraction of this material as a lipid-soluble acid. He named it 
"prostaglandin" as an acknowledgement to its source, the prostate 
gland. 
An interval of twenty years was then necessary to develop 
techniques which showed that the prostaglandins were actually 
a family of compounds. These technical advances allowed 
Bergstrom and Sjovall in 1957 to isolate two prostaglandins, 
prostaglandin E^ (PGE) and PGF]a , in crystalline form. Five 
years later their structure was elucidated. Eventually several 
members of the family were characterized. 
With an understanding of the general structure of prosta¬ 
glandins their relationship to essential fatty acids became 
obvious. It was then realized that acidic lipid autocoids of 
several different tissues were in fact prostaglandins. Finally, 

in 1964, Bergstrom with his group and Van Doys together with his 
associates independently synthesized PGE2 from arachidonic acid 
obtained from homogenates of the vesicular glands of sheep 
(Samuelsson, 1972). 
PG Chemistry 
The prostaglandins are a family of compounds which can be 
considered derived from a hypothetical compound with the trivial 
name prostanoic acid and has the following structure (Goodman 
and Gilman, 1975): 

The different classes of prostaglandins are determined by 
the constituents of the cyclopenrane ring. These are shown 
for prostaglands of the E and Fa series: 
These are considered the "primary prostaglandins" since they are 
the most abundant and most intensively studied. There are five 
other classes: Fg , A, B, C, and D. These main classes are 
further subdivided according to the number of side chains with 
double bonds. This is denoted by the subscript 1, 2, or 3, and 
reflects the fatty acid precursor. Those derived from 5,8,11,14- 
eicosatetraenoic acid (arachidonic acid), for example, carry the 
subscript 2. 
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PG Biosynthesis 
Prostaglandins can be found in all of the body's tissues. 
They are drived ultimately from linoleic acid (cis-5, cis-3- 
octadecadienoic acid) the main natural essential fatty acid which 
can be produced only be vegetable tissue and so must be incorporated 
in the diet. It is believed that linoleic acid is deposited into 
cell membranes as esterified forms of dihomo-y-linolenic acid 
and arachidonic acid. These precursor fatty acids depend on the 
enzyme phospholipase a for their release from the cellular phos¬ 
pholipid stores when needed as substrate. Other factors, including 
oxygen and glutathion, are essential for biosynthesis. This 
released precursor fatty acid, e.g. arachidonic acid, is then 
acted on in a stepwise manner by a complex of microsomal enzymes 
referred to as "prostaglandin synthetase". A cyclic peroxide 
derivative, endoperoxide, is formed from unesterified precursor 
acid by oxygenation and cyclization. It is then either isomerized 
to a PGE compound by endoperoxide isomerase or reduced to a PGFa 
compound by endoperoxide reductase. With arachidonic acid, then, 
the products are either PGE2 or PGF9a. These are the most 
abundant mammalian prostaglandins. The other prostaglandins, A, 
B, and C, are formed from PGE by dehydration and isomerization 
and is species dependent (Samuelsson, 1972; Hamberg and Samuelsson, 
1973). 
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PG Catabolism 
Prostaglandins E and F are relatively stable in blood apart 
from the slow isomerization that occurs between then. They are, 
however, rapidly inactivated and degraded by tissue-bound enzymes, 
notably 15-hydroxy-prostaglandin dehydrogenase and A-13 prostaglandin 
reductase, with some ninety to one hundred per cent being destroyed 
during a single passage through the liver or the lungs (Ferreira, 
1S67). This implies then, that prostaglandins should not be 
considered as circulating hormones, and in fact, their concentration 
in circulating plasma are extremely low. Their physiological 
activities are thus on the cellular level and are probably limited 
to the organ where they are produced. PGAs are an exception, 
however, in that substantial amounts escape degradation in the 
pulmonary and hepatic circulation and their effects are more pro¬ 
longed (Horton, 1969). 
PG Mechanism of Action 
The way in which the prostaglandins exert their effects has 
been elucidated only partially. Current thought revolves around 
two major factors involved in regulation of cellular function, 
namely, calcium and cyclic AMP, Receptors for prostaglandins are 
apparently involved (Weeks, 1972). Many of the observed effects of 
prostaglandin are calcium dependant. In most tissues prostaglandins 
(especially PGE) increases the concentration of 3',5'-AMP and in 
a few (adipose tissue, uterus) it lowers the concentration. It is 
thought that these effects of prostaglandins are mediated by adenylate 
cyclase. 

Cardiovascular Pharmacological Properties of PG 
The pharmacological effects of prostaglandins are many 
and varied and depend on the species and on the specific prosta¬ 
glandin. No other class of autacoids has been found to have 
such diverse effects. 
Since the cardiovascular system is of particular interest 
in this paper, our emphasis will be limited to it. PGEs and 
PGAs are potent vasodilators in most vascular beds in most species 
including the coronary bed of the dog. The dilation seems to 
involve arterioles, precapillaries, sphincters, and postcapillary 
venules. Bloor and co-workers found that "in the intact un¬ 
anaesthetized dog PGA, and PGE, significantly increased coronary 
blood flow before affecting heart rate, cardiac output and mean 
aortic blood pressure, or peripheral vascular resistance" 
(Bloor, 1973). They concluded that PGA^ and PGE]_ are primary 
coronary vasodilators. Needleman and his group found that most 
potent vasoconstrictor substance in the body, Angiotensin II, 
produced coronary dilation when it resulted in the release of a 
prostaglandin-like substance by the heart. Coronary dilation 
produced by bradykinin also appeared to be mediated by endogenous 
coronary biosynthesis of a prostaglandin-like substance (Needleman, 
1975). Cardiac output is generally increased by PGs E, F, and A. 
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PGs E and A also generally cause a fall in systemic blood pressure 
and blood flow is increased to most organs including the heart. 
An increase in myocardial, contractile force in dogs with 
an intact circulation has been noted with PGE- and PGF- compounds 
(Gudbjarnason, 1975). The positive inotropic action of PGE- 
compounds is not blocked by propranolol (Bergstrom, 1968; Nakano, 
1971; Gudbjarnason, 1975). 
Capillary permeability is increased by PGs of the E and F 
series. PGE2 may have antiarrhythmic properties according to some 
studies (Mest, 1973). 
Physiologic Role of Endogenous PG 
Limas and Cohn (1973) have reported that the myocardium 
possesses the necessary enzymatic machinery for the in situ pro¬ 
duction of prostaglandins. They found that the microsomal-fraction 
prepared from canine myocardium contained an active prostaglandin 
synthetase which was capable of forming PGE2 from arachidonic acid 
in the presence of reduced glutathione and cofactors such as 
1-adrenaline, hydroquinone, and p-araino-phenol. The mechanisn 
that turns on the biosynthetic enzyme was not determined. Previously, 
however, McGiff and his co-workers had shown that a prostaglandin¬ 
like substance was released from the kidney during renal ischemia 
(McGiff, 1970). Similar implications of a prostaglandin role in 
vasomotor autoregulation have been shown in other tissues including 
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kidney (Herbaczynska-Cedro, 1974), brain (Pickard, 1973), and 
uteroplacental bed (Franklin, 1975). The biosynthesis and release 
of prostaglandins into the blood stream under hypoxic conditions 
was demonstrated in the isolated perfused rabbit heart in 1974 
(Wenmalm, 1978) and 1957 (Block, 1975). Similar findings were 
noted in the open-chest dog where an increase in prostaglandins 
in coronary venous blood were noted during postocclusive reactive 
hyperemia (Alexander, 1975). Coronary occlusion in the canine 
heart-lung preparation has produced similar results (Kraemer, 1973). 
The conclusion of researchers in this area was that prostaglandins 
may be involved in the autoregulatory response of the myocardium 
to ischemia. Hutton (1973) demonstrated that in comparison to the 
preinfarction state, prostaglandin E increased coronary blood flow 
to ischemic areas. Berger (1977) demonstrated the release of 
prostaglandins E and F from the canine heart during coronary 
occlusion and the release of prostaglandin F from the human heart 
during pacing-induced angina pectoris. Like Hoor and Vergroesen 
(1975) we must conclude that prostaglandins are most probably 
involved in the regulation of coronary flow under normal and hypoxic 
conditions. 
Aspirin Inhibition of PG Synthesis 
A group of workers in England, led by Vane, discovered in 
1971 that aspirin-like drugs inhibited the biosynthesis of prosta- 
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glandins. The evidence suggested that aspirin-like drugs 
specifically inhibit the enzyme system which synthesizes prosta¬ 
glandins, i.e. prostaglandin synthetase (Vane, 1971). Other groups 
supported these findings (Smith, 1971; Ferreira, 1971). In retro¬ 
spect, however, several earlier clues had been noted. Piper and 
Vane (1969) had noted that a substance released by guinea pig lungs 
during anaphylaxis, which they named rabbit aorta constrictor 
substance (RCS), was blocked by aspirin. Responses to arachidonic 
acid in some preparations were also inhibited by aspirin, and 
arachidonic acid was found to release RCS. Men treated with con¬ 
ventional doses of aspirin demonstrated a clear-cut inhibition of 
prostaglandin synthesis as measured by the prostaglandin content of 
semen or excretion of its principle metabolite in the urine. The 
evidence, then, clearly demonstrates that aspirin is an effective 
inhibitor of prostaglandin synthesis and release. 
Platelet aggregation in response to injured blood vessels 
is mediated by several mechanisms of which at least two are thought 
to be inhibited by aspirin. Exposed connective tissue causes 
platelets to initially aggregate at the site of injury in part 
through the enzymatic action of collagen glucosy1-transferase which 
can be found in platelet membranes. Aspirin interferes with this 
activity. As they aggregate the platelets synthesize and release 
thromboxane A2, an enzymatic product of PGH2 (cyclic endoperoxide) 
the intermediate between arachidonic acid and the other prostaglandins. 

This thromboxane causes further aggregation and the release of 
vessicle stored adenosine diphosphate (ADP). ADP causes more 
platelet aggregation with its ensuing ADP release setting in motion 
a chain reaction leading to a platelet plug. Aspirin blocks the 
release of ADP by interfering with the synthesis of thromboxane A2 
and aborts the entire process (Goodman and Gilman, 1975; Christ 
and Van Dorp, 1972). 
ST-Segment Mapping 
It has been known since 1920 that myocardial injury in a 
patient with coronary heart disease is indicated by ST-segment 
changes in the peripheral electrocardiogram (Pardee, 1920). Thirteen 
years later Wilson and his group confirmed that ST-segment alterations 
occur with coronary artery ligation by placing an electrode on the 
epicardial surface of the dog heart (Wilson, 1933). Recently, ST- 
segment mapping has had wide application in confirming and quanti¬ 
fying regional myocardial ischemia. The assumption has always been 
that previous clinically and empirically derived relationships 
between precardial electrogram alterations in the ST-segment and 
the presence of ischemic myocardium are equally applicable to inter¬ 
pretation of changes recorded from the epicardial surface. Sampson 
(1959) suggested that the ST-segment alteration appears to be 
related to an incomplete depolarization or an early repolarization 
of the ischemic tissue during electrical systole. 
There is considerable evidence that the epicardial ST-segment 
elevation directly reflect myocardial cellular injury (Maroko, 1971). 
i n 

Maroko (1971) obtained results which demonstrate a close corre¬ 
lation between the extent and magnitude of early elevation of ST- 
segments in epicardial recordings after acute coronary artery 
occlusion and the later development of cellular damage, as evidenced 
by depression of myocardial CPK activity in specimens from the 
same site. 
To attribute change in ST-segments exclusively to alterations 
due to ischemia would be misleading (Braunwald, 1976). It is, 
however, profoundly influenced by perfusion. Other variables such 
as PO2, PCO9, ventricular conduction, sympathetic stimulation, and 
varying vectors established by the three dimensional geometry of 
the ischemic myocardium affect ST-segment elevation changes. 
Kjekshus and co-workers, nevertheless, established a good correlation 
between the ST-segment changes and the balance between myocardial 
oxygen supply and demand with subsequent evolution of myocardial 
necrosis (Kjekshus, 1972). 
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Materials and Methods 
These experiments were designed to evaluate the effects 
of inhibition of prostaglandin synthesis by acetylsalicylic acid 
(aspirin) on myocardial ischemia as measured by ST-segment elevation 
(ST t). 
Thirty healthy dogs of both sexes, weighing fifteen 
through thirty-six kilograms, were initially anesthetized with 
Surital (Thiamylal 4%, 0.5 ml/kg), intubated, and mechanically 
ventilated on room air (Harvard model 607). Anesthesia was then 
continued with Chlorolose-urethane (4.5 g urethane, 0.45 g 
chlorolose. Respiratory settings were manipulated to maintain the 
pH, oxygen tension (PO2), and carbon dioxide tension (Pco2) of the 
arterial blood gases within the following ranges: pH 7.35 to 7.45, 
PO2 95 to 115 rrmHg, and PC02 25 to 35 mriHg. Changes were not made 
in these parameters after coronary artery occlusion. 
A left thoracotomy was performed in the fourth left inter¬ 
costal space by gross dissection and electrosurgery. The heart 
was then suspended in a pericardial cradle. The left anterior 
descending artery (LAD) was dissected free approximately 3 cm from 
its origin and isolated. A snare was placed loosely around the 
LAD. The left atrium was then cannulated and catheters inserted 
into both right and left femoral arteries and the left femoral vein. 
Two thousand U heparin IV was administered to every animal. Arterial 
pressures were recorded with a physiological pressure transduced 
(Statham, Model No, P23Gb) and the lead II electrocardiogram was 

monitored continuously. All recordings were done on a DR-12 
Electronics for Medicine multichannel recorder. A bolus of 
Lidocaine (50 mg) was given just prior to occlusion. All animals 
were then placed on a Xylocaine drip (1 mg/min). 
Regional myocardial blood flow was measured using micro¬ 
spheres labelled with cerium-141, strontium-85, and chromium-51. 
The results of these data are presented elsewhere (H. Johnson, 
1979). 
Epicardial ST-segment mapping was performed according to the 
method described by Maroko (1971). The epicardial electrograms 
were recorded on unipolar leads at a sensitivity of 1 millivolt 
per nm amplitude from approximately eighteen sites on the anterior 
surface of the left ventricle by means of a saline-soaked cotton 
wick electrocardiographic probe. Sites for mapping were chosen from 
areas supplied by the occluded artery and from areas remote from it 
that were supplied by the left circumflex artery and which were 
presumably normally perfused. ST-segment elevation was measured 
100 msec from beginning of the QRS complex. The T-P segment was 
considered the isoelectric line. The mean of five complexes was 
used as the value for each electrode site. Sites demonstrating a 
QRS complex of greater than 65 msec in duration were held to be 
manifestations of local conduction disturbances and were therefore 
excluded from analysis for the entire experiment. This occurred 
in approximately 12% of mapping sites. The sum of the average ST- 
segment elevation for each site and the number of sites with ST- 
segment elevation exceeding two millivolts were determined. 
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Arterial blood gases were monitored and salicylate levels 
were obtained from blood samples drawn after the occlusion. 
Clinical laboratory measurements of serjm aspirin levels showed 
that 30 mg/kg of aspirin injected as an IV bolus produced a mean 
salicylate level of 10 mg/dl (range G-14) 17 min later while 
60 mg/kg produced a mean salicylate level of 19.6 mg/dl (range 14-23). 
Protocol 
The animal model was prepared as described above and ST- 
segment maps were made. The left anterior descending coronary 
artery was then occluded. At 30 and 55 min post occlusion regional 
myocardial blood flow was measured and epicardial ST-segment mapping 
was performed. Then, at 63 min post occlusion ten dogs received 
30 mg/kg aspirin IV: five dogs received 60 mg/kg aspirin; and five 
dogs received only the aspirin vehicle, 50 ml of buffered saline. 
Ten additional dogs died after occlusion but before administration 
of aspirin or the vehicle. These animals were excluded from the 
data analysis. Both regional myocardial blood flowmeasurenents and 
epicardial ST-segment mapping were performed again at 75 and 90 
min post occlusion. Arterial blood gases and salicylate levels 
were obtained at 80 min post occlusion. 
At 95 minutes the heart was excised rapidly and used in 
the determination of regional blood flow. 
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Statistical Methods 
Data from the animals treated with 30 mg/kg of aspirin 
and 60 mg/kg of aspirin were each compared to those treated with 
the saline alone at 60, 75, and 90 minutes after occlusion by 
unpaired t-test. Post occlusion values obtained before and after 
the administration of aspirin were also compared within each 
experimental dosage level by unpaired t-test. Probability (p) 
less than 0.01 was considered significant. 
Results 
Heomdynamic measurements, mean aortic blood pressure and 
heart rate, were not significantly altered by occlusion or aspirin 
administration. When analysed as the double product, blood pressure 
multiplied by heart rate, the values for the control animals at 
60, 75, and 90 min after occlusion (meant S.D. in units of 
run Hg X beats X 10*- 
min ), 20.4±1.0, 20.0±0.8, 20.4±2.0, were not 
significantly different from those of the animals receiving aspirin, 
19.6±1.6, 20.2±1.8, 19.2±1.6. 
Values for ZST obtained by the. dogs given the aspirin vehicle 
only, the control animals, at 60, 75, and 90 min were: (meant S.E.M. 
in units of mV) 3.51t0.31, 2.53t0.28, 2.49t0.33. The dogs receiving 
30 mg/kg aspirin had values which were: 3.62±0.19, 3.24t0.17, 
3.86t0.25. Those which were given 60 mg/kg: 2.68t0.29, 4.81±0.37, 
3.67t0.37. Thus the values obtained at 60 min post coronary occlusion 
but before the administration of aspirin for the sum of ST-segment 
elevation wore not significantly different (p<0.01) from those 
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obtained at either 75 min post occlusion, i.e. 13 min after 
aspirin administration, or 90 min post occlusion. Myocardial 
ischemic injury as measured by ST-segment elevation (1ST) is not 
affected by acetylsalicylic acid (aspirin) at either 30 mg/kg or 
60 mg/kg. 
A similar lack of significant difference was noted for 
the number of sites measured with greater than 2 mV ST-segment 
elevation (NST). Again, the values for the control animals 
4.00^:0.26, 4.00±0.26, 3.40±0.30 were not significantly different 
from the animals receiving 30 mg/kg aspirin: 6.40±0.13, 6.00±0.14, 
6.14±0.25 or those receiving 60 mg/kg: 4.80±0.32, 5.00±0.35, 
4.60±0.32. 
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DISCUSSION 
Berger's study (1977) demonstrated the release of prosta¬ 
glandins E and F from the canine heart during myocardial ischemia. 
The release occurred within 10 minutes of left anterior descending 
occlusion in all animals and persisted until the animal died. 
Kirmser (1976) demonstrated that if Indomethacin, which 
is known to block prostaglandin synthesis, is given after coronary 
occlusion in an identical preparation, flow to ischemic zones 
falls and ST-segment elevation increases. 
Nevertheless, the exact physiologic importance of cardiac 
prostaglandin release during ischemia retains unclear, although 
it is thought that its local availability following a decrease in 
coronary perfusion may affect the cardiac response to ischemia. 
In 1977, Ogletree found that Indomethacin pretreatment pre¬ 
vented increases in cardiac prostaglandin release, but it did not 
influence other biochemical changes or the electrocardiographic 
response to ischemia. Specifically, Indomethacin did not alter 
the degree of ST-segment deviation at any time, according to that 
study. 
The data for aspirin are similarly conflicting. In 1973, 
Flower and others showed that aspirin inhibits the enzyme system 
which synthesizes prostaglandins in many tissues. In the same 
year, however, there was a report that aspirin did not influence 

the invitro activity of isolated myocardial prostaglandin synthe¬ 
tase (Limas, 1973). Halushka (1977) has shown that doses of 30 
mg/kg IV of aspirin in dogs completely block platelet aggregation 
and platelet arachidonic acid metabolism but have no affect on myo¬ 
cardial synthesis of irrmunoreactive prostaglandin E-like material. 
H. Johnson (1979) has shown in our preparation that following 
coronary occlusion there is a fall in coronary flow which then gradually 
recovers normal control levels in animals receiving no intervention. 
Aspirin, however, resulted in a decrease in coronary flow to moderately 
ischemic and severely ischemic zones. There was also a concomitant 
decrease in the endocardial-epicardial perfusion ratio. Similar 
results have been obtained with Indomethacin (Kirmser, 1976) suggesting 
that both drugs have similar affects on coronary flow. 
Kjekshus (1972) has argued convincingly that ST-segment changes 
are a reliable index of myocardial ischemia. Ung (1976), using the 
criterion of ST-segment changes, concluded that aspirin pretreatment 
reduces the extent of ischemic injury in the open-chest dog following 
acute coronary occlusion. In his protocol, however, the animals were 
used as their own control with aspirin given before a second coronary 
occlusion. This represents a substantial difference from our procedure 
and may explain the disparity in results. In our experiments there 
v/ere no significant changes in iST or NST following aspirin adminis¬ 
tration in post-coronary occlusive animals, possibly suggesting that 
abolishing platelet prostaglandin synthesis does not affect the myo¬ 
cardial response to coronary occlusion. 
The enzymes responsible for cardiac prostaglandin biosynthesis 
may be differentially insensitive to inhibition by aspirin (Limas, 1973). 

Perhaps we are seeing the competing effects of platelets and 
coronary flow both of which are moderated b37 prostaglandins. 
Aspirin is now being used by some researchers as a prophylactic 
to prevent coronary artery thrombosis. The experiments by Ung 
(1976) suggest amelioration of the effects of coronary occlusion. 
However, it may not since our results indicate that aspirin does 
not reduce the extent of ischemic injury in the open-chest dog 
following acute coronary occlusion, and that it decreases regional 
flow. Thus, despite similar effects on coronary flow, aspirin 
and Indomethacin have different effects on epicardail ST-segment 
elevation. This may be due either to dose or to drug-specific 
differences in the inhibition of myocardial prostaglandin. 

TABLE I 
1ST (mV) 
Time Post 
Occlusion 
Aspirin 
dose 
Mean Standard 
deviation 
Standard 
error 
60 min control 3.51 3.06 0.31 
30 mg/kg 3.62 2.66 0.19 
60 mg/kg 2.68 2.90 0.29 
75 min control 2.53 2.82 0.28 
30 mg/kg 3.24 2.47 0.17 
60 mg/kg 4.81 5.13 0.51 
90 min control 2.49 3.27 0.33 
30 mg/kg 3.87 2.98 0.25 
60 mg/kg 3.67 3.73 0.37 

TABLE 2 
NST 
Time Post Aspirin Mean Standard 
Occlusion dose deviation 
60 min control 4.00 
30 mg/kg 6.40 
60 mg/kg 4.80 
2.61 
1.91 
3.25 
75 min control 4.00 
30 mg/kg 6.00 
60 mg/kg 5.00 
2.61 
2.00 
3.52 
90 min control 3.40 
30 mg/kg 6.14 
60 mg/kg 4.60 
3.01 
3.00 
3.20 
Standard 
error 
0.26 
0.13 
0.23 
0.26 
0.14 
0.35 
0.30 
0.25 
0.32 
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